Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access.

Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted radiotherapy in a single, personalized approach. Over the past decade, the field has gained substantial momentum, with several radiopharmaceuticals now incorporated into clinical practice, most notably for neuroendocrine tumors and prostate cancer. The pipeline of novel agents continues to grow, offering promising therapeutic options for patients with cancers resistant to conventional therapies.

Evaluating the diagnostic utility of [⁶⁸Ga]Ga-Pentixafor in solid tumors: a systematic review.

The C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a critical molecular imaging target in various malignancies due to its central role in tumor progression, metastasis, and resistance to therapy. Among the imaging modalities developed to exploit this target, [68Ga]Ga-Pentixafor-a positron emission tomography (PET) radiopharmaceutical-has shown potential in diagnostic imaging. However, its diagnostic utility in solid tumors remains relatively underexplored, particularly in comparison to the widely utilized [18F]fluorodeoxyglucose ([18F]FDG) PET/CT.

Clinical Characteristics and Treatment Outcomes of Colorectal Cancer in Jordan, a Resource-Restricted Country.

Purpose: Colorectal cancer is the second most prevalent cancer in Jordan and remains the second leading cause of cancer-related deaths in both men and women. This manuscript aims to explore the situation of colorectal cancer in Jordan, a resource-restricted country, and provide insights into clinical presentation and treatment outcomes.

Materials And Methods: We reviewed all reports from the Jordan Cancer Registry over the past 20 years.

[Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review.

[Lu]Lu-FAPI, a novel and innovative radioligand targeting fibroblast activation protein (FAP), has rapidly emerged as a powerful therapeutic strategy for difficult-to-treat solid malignancies. FAP is highly expressed in cancer-associated fibroblasts (CAFs) across a broad spectrum of solid malignancies, thereby providing a valuable therapeutic target for novel radiopharmaceuticals. To date, a growing body of preliminary studies has explored the therapeutic potential of [Lu]Lu-FAPI in oncology, with numerous ongoing clinical trials currently recruiting patients to substantiate its evolving prospects.

Targeted alpha therapy in prostate cancer: review of available agents in clinical practice.

Targeted alpha therapy (TAT) has shown promise in prostate cancer patients, both hormone-sensitive and castration-resistant, with or without prior treatment. TAT's radiobiological properties explain why it is more potent than other forms of ionizing radiation, such as the clinically approved [Lu]Lu-PSMA-617. Although most TAT agents used in compassionate care or clinical trials target the prostate-specific membrane antigen (PSMA), some alternatives are yet to be used clinically, some of which aim to address PSMA-negative prostate cancer.

PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review.

Introduction: Neuroendocrine prostate cancer (NEPC) is a rare cancer subtype with significant prognostic implications. This systematic review aims to explore the current landscape of positron emission tomography (PET) imaging and radionuclide therapy in this rare entity.

Evidence Acquisition: The Scopus and PubMed online databases were systemically reviewed to identify relevant studies on the topic of interest.

Diagnostic efficacy of [F]FDG PET/CT and [F]FDG PET/MRI in preoperative staging of locoregional urinary bladder cancer: a systematic review and Meta-Analysis.

Background: This systematic review and meta-analysis aims to evaluate the diagnostic utility of [F]Fluorodeoxyglucose ([F]FDG) PET/CT and [F]FDG PET/MRI in preoperative locoregional staging of bladder cancer (BC).

Methods: A comprehensive search of PubMed and Scopus databases was conducted up to February 26, 2025, to collect and analyze diagnostic accuracy parameters. Statistical analyses, including publication bias assessment, interstudy heterogeneity evaluation, and effect size adjustment, were performed using Stata software, with a significance threshold set at p < 0.

Complex immunotherapy-mediated response patterns depicted on serial F-FDG PET imaging of Hodgkin lymphoma patient undergoing pembrolizumab therapy.

Over the past decade, the role of F-Fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing treatment response for lymphoma patients undergoing immunotherapy has been extensively investigated. The advent of immunotherapy has challenged the utility of the established Lugano criteria, prompting the development of novel immunotherapy-specific response criteria now employed in clinical practice. Following F-FDG PET/CT evaluation after up to eight immunotherapy cycles, patients are typically transitioned to conventional imaging modalities if immunotherapy continuation is warranted.

Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma.

Introduction: Primary Mediastinal Large B Cell Lymphoma (PMLBCL) is a rare but aggressive B-cell lymphoma. This study compares the outcomes and toxicities of DA-EPOCH-R (Dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin in combination with rituximab) and RCHOP-21 (rituximab, cyclophosphamide, doxorubicin, and vincristine, every 21 days) in the treatment of newly diagnosed PMLBCL.

Methods: We retrospectively reviewed the medical records of adults (>18 years) diagnosed with PMLBCL and treated at our center from 2010 to 2023.

Integrating PET/CT into breast cancer care: a review of recent developments.

Introduction: Breast cancer (BC) is the most common malignancy in women, classified by histopathological type, grade, receptor status, and stage. PET/CT, particularly with F-FDG, plays a vital role in staging, detecting metastases, and assessing treatment response. This review explores the role of PET/CT in BC management and emerging radiotracers for enhanced diagnosis.

Short-term Prostate-specific Antigen Pseudoregression Following [ 177 Lu]-Prostate-specific Membrane Antigen Therapy : Tackling Prostate-specific Antigen Decline Limitations in Patient With Metastatic Castration-resistant Prostate Cancer.

A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [ 177 Lu]Lu-prostate-specific membrane antigen (PSMA) therapy. Despite declining prostate-specific antigen (PSA) levels and pain relief throughout the first 4 months of [ 177 Lu]Lu-PSMA therapy, follow-up [ 68 Ga]Ga-PSMA PET/CT revealed progressive skeletal involvement. A bone marrow biopsy confirmed fulminant metastatic castration-resistant prostate cancer infiltration.

The Poor Prognostic Stigma of Hepatic Superscan on F-FDG PET Imaging.

Pancreatic exocrine carcinoma (PEC) is a lethal malignancy with high mortality rates because of its aggressive nature and frequent late-stage diagnosis. When histopathological diagnosis becomes unfeasible because of patient deterioration, clinicians must rely on clinical, biochemical, and radiological findings. This case report describes a 78-year-old woman with aggressive PEC visualized through F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography.

The value of artificial intelligence in PSMA PET: a pathway to improved efficiency and results.

Introduction: This systematic review investigates the potential of artificial intelligence (AI) in improving the accuracy and efficiency of prostate-specific membrane antigen positron emission tomography (PSMA PET) scans for detecting metastatic prostate cancer.

Evidence Acquisition: A comprehensive literature search was conducted across Medline, Embase, and Web of Science, adhering to PRISMA guidelines. Key search terms included "artificial intelligence," "machine learning," "deep learning," "prostate cancer," and "PSMA PET.

Hepatic Cyst Radioiodine Uptake on Whole-Body Scan in Differentiated Thyroid Cancer: Implications for Lesion Characterization and Misdiagnosis Avoidance.

Radioactive iodine (RAI) imaging constitutes a fundamental diagnostic tool in post-operative thyroid cancer management. A diverse spectrum of uptake patterns, encompassing both physiological and pathological entities, has been reported in patients undergoing RAI studies. Particularly, a variety of non-thyroidal conditions can present with unusual patterns of RAI uptake in the liver, complicating diagnosis.

Enhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using Ga-FAPI PET/CT Compared to F-FDG PET/CT: A Case Report.

Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT) in diagnosis and staging of DMPM are well-established, the utility of gallium-68 fibroblast activating protein inhibitor ( Ga-FAPI) PET/CT in detecting disease recurrence remains an area that requires further research and validation, with limited literature. Implementing FAPI PET/CT for these cases may provide superior lesion detectability and higher reporter confidence, prompting the need for further studies to investigate the potential future role of FAPI theranostics in guiding treatment decisions for DMPM.

Tracing the global evolution of PSMA-targeted radioligand therapy in prostate cancer: clinical advancements, future directions, and challenges.

Prostate-specific membrane antigen-targeted radioligand therapy (PSMA RLT) has recently emerged as a promising treatment for patients with metastatic prostate cancer. Building on the success of PSMA PET diagnostics, PSMA RLT has attracted interest from both research institutions and pharmaceutical companies, leading to a progressive increase in clinical trials over the past decade. In 2022, the first PSMA RLT agent, [Lu]Lu-PSMA-617, was approved by the FDA and EMA for the treatment of mCRPC patients progressing after standard therapies.

Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review.

The treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC) has traditionally relied on a multimodal approach, combining surgery, radiation therapy (RT), and chemotherapy. While chemotherapy plays a critical role in improving cure rates and functional outcomes, its substantial toxicity remains a major concern, particularly in older patients. These challenges are especially relevant for those who are unfit for chemotherapy or decline conventional concurrent chemoradiotherapy (CCRT), highlighting the need for alternative therapeutic options.

Diagnostic pitfalls in [68Ga]Ga-DOTATATE PET/CT imaging: a systematic review.

[68Ga]Ga-DOTA-Tyr3-octreotate ([68Ga]Ga-DOTATATE) is an established somatostatin receptor imaging agent that has demonstrated superior efficacy in visualizing neuroendocrine tumors (NETs) and meningiomas compared with traditional [ 111 In]In-octreotide imaging. Despite its enhanced affinity and sensitivity, [68Ga]Ga-DOTATATE imaging is not without challenges. To date, numerous diagnostic pitfalls and false-positive findings have been reported.

Quality of life in thyroid cancer survivors with and without permanent hypoparathyroidism.

Purpose: Hypoparathyroidism (HypoPT) is one of the most common complications of surgical treatment for thyroid cancer and afflicated patients often report symptoms or impairments in quality of life (QoL). We aimed to investigate differences in various QoL domains between thyroid cancer survivors with and without permanent hypoparathyroidism.

Methods: Thyroid cancer survivors with a minimum of 1.

Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.

Radioligand therapy (RLT) has garnered significant attention due to the recent emergence of innovative and effective theranostic agents, which showed promising therapeutic and prognostic results in various cancers. Moreover, understanding the interaction between different types of radiation and biological tissues is essential for optimizing therapeutic interventions These concepts directly apply to clinical RLTs and play a crucial role in determining the efficacy and toxicity profile of different radiopharmaceutical agents. Personalized dosimetry is a powerful tool that aids in estimating patient-specific absorbed doses in both tumors and normal organs.

Therapeutic potential of FAPI RLT in oncology: A systematic review.

This systematic review aims to examine the safety and efficacy of fibroblast activation protein inhibitor (FAPI) radioligand therapy (RLT) for various epithelial neoplasms. PubMed, Web of Science, and Scopus databases were searched up to Jan 4, 2025, for studies involving FAPI RLT in various cancers. Data extraction focused on exploring safety and efficacy of FAPI RLT.